PMID- 27308473
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160616
LR  - 20201001
IS  - 2372-3556 (Print)
IS  - 2372-3556 (Electronic)
IS  - 2372-3556 (Linking)
VI  - 2
IP  - 3
DP  - 2015 Jul-Sep
TI  - Counteracting oxidative phosphorylation-mediated resistance of melanomas to MAPK 
      pathway inhibition.
PG  - e991610
LID - 10.4161/23723556.2014.991610 [doi]
LID - e991610
AB  - Mitochondrial oxidative phosphorylation (OxPhos) induces resistance to MAPK 
      pathway inhibitors in melanoma. However, therapeutic targeting of mitochondria is 
      challenging. In a recent study, we showed that inhibition of mTOR kinase activity 
      resensitized resistant melanomas by indirectly inhibiting OxPhos via a novel 
      mechanism. Here, we discuss the implications of these findings.
FAU - McQuade, Jennifer L
AU  - McQuade JL
AD  - Divison of Cancer Medicine and The University of Texas M.D. Anderson Cancer 
      Center ; Houston, TX, USA.
FAU - Vashisht Gopal, Yn
AU  - Vashisht Gopal Y
AD  - Department of Melanoma Medical Oncology; The University of Texas M.D. Anderson 
      Cancer Center ; Houston, TX, USA.
LA  - eng
PT  - Journal Article
DEP - 20150123
PL  - United States
TA  - Mol Cell Oncol
JT  - Molecular & cellular oncology
JID - 101642411
PMC - PMC4905309
OTO - NOTNLM
OT  - BRAF
OT  - MEK
OT  - MITF
OT  - NRAS
OT  - PGC1alpha
OT  - metabolism
EDAT- 2016/06/17 06:00
MHDA- 2016/06/17 06:01
PMCR- 2016/01/23
CRDT- 2016/06/17 06:00
PHST- 2014/11/11 00:00 [received]
PHST- 2014/11/20 00:00 [revised]
PHST- 2014/11/21 00:00 [accepted]
PHST- 2016/06/17 06:00 [entrez]
PHST- 2016/06/17 06:00 [pubmed]
PHST- 2016/06/17 06:01 [medline]
PHST- 2016/01/23 00:00 [pmc-release]
AID - 991610 [pii]
AID - 10.4161/23723556.2014.991610 [doi]
PST - epublish
SO  - Mol Cell Oncol. 2015 Jan 23;2(3):e991610. doi: 10.4161/23723556.2014.991610. 
      eCollection 2015 Jul-Sep.